Abstract
Monoclonal gammopathies (MG) are a group of clinical entities characterized by the clonal expansion of monoclonal immunoglobulin (M-protein) secreting plasma cells (PC). This document presents the consensus recommendations of the Spanish Society of Laboratory Medicine (SEQCML) and the Spanish Society of Hematology and Hemotherapy (SEHH) for the study of MG. The recommendations were established based on scientific evidence and the opinion of experts in MG from the clinical laboratory and clinical hematology fields. Recommendations are proposed for the diagnosis of MG and for patient follow-up according to the type of MG and whether or not the patient is undergoing treatment, and to monitor the disease stability, response to therapy and disease progression. With respect to the diagnosis, we describe the most recent criteria and classification established by the International Myeloma Working Group (IMWG) for multiple myeloma (MM), smoldering MM, monoclonal gammopathy of undermined significance (MGUS) and other related entities. Indications are given about the analytical requirements and application of the different serum and urine laboratory tests (study, detection, identification and measurement of M-protein) and the bone marrow study. Recommendations on the clinical laboratory results report model are established to harmonize and ensure that all relevant information is available, including its content, expression, and interpretive comments.
-
Research ethics: Not applicable.
-
Informed consent: Not applicable.
-
Author contributions: The authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: María C Cárdenas, Noemí Puig, David Pérez-Surribas, Juan Flores-Montero, María Ortiz-Espejo and Elena Cruz-Iglesias state no conflict of interest. Ramón García-Sanz states: Honoraria: Amgen, Millennium/Takeda, Janssen, Incyte, Astellas, BeiGene, AstraZeneca, Pfizer. Research funding: Novartis, Gilead, Astellas, Janssen. Advisory boards: Amgen, Pharmacyclics, Millennium/Takeda. Research support/PI: Spanish National Health System, Regional Health System (Castilla y León), Spanish Association Against Cancer. Ex-president: Spanish Society of Hematology and Hemotherapy. Employee: Spanish National Health System. Javier De la Rubia states: Honoraria: Takeda, Janssen, BMS, Pfizer, GSK, Oncopeptide, Sanofi. Research funding: Takeda. Advisory boards: Amgen, Janssen, Sanofi, GSK. Employee: Spanish National Health System.
-
Research funding: None declared.
References
1. Rajkumar, SV, Dimopoulos, MA, Palumbo, A, Blade, J, Merlini, G, Mateos, MV, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5.Search in Google Scholar PubMed
2. Merlini, G, Stone, MJ. Dangerous small B-cell clones. Blood 2006;108:2520–30. https://doi.org/10.1182/blood-2006-03-001164.Search in Google Scholar PubMed
3. Ocio, EM, Richardson, PG, Rajkumar, SV, Palumbo, A, Mateos, MV, Orlowski, R, et al.. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014;28:525–42. https://doi.org/10.1038/leu.2013.350.Search in Google Scholar PubMed PubMed Central
4. Liwing, J, Uttervall, K, Lund, J, Aldrin, A, Blimark, C, Carlson, K, et al.. Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population. Br J Haematol 2014;164:684–93. https://doi.org/10.1111/bjh.12685.Search in Google Scholar PubMed
5. Willrich, MAV, Katzmann, JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med 2016;54:907–19. https://doi.org/10.1515/cclm-2015-0580.Search in Google Scholar PubMed
6. Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328–46. https://doi.org/10.1016/s1470-2045(16)30206-6.Search in Google Scholar PubMed
7. Tate, JR, Keren, DF, Mollee, P. A global call to arms for clinical laboratories – harmonised quantification and reporting of monoclonal proteins. Clin Biochem 2018;51:4–9. https://doi.org/10.1016/j.clinbiochem.2017.11.009.Search in Google Scholar PubMed
8. Katzmann, JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009;30:105–11.Search in Google Scholar
9. Dispenzieri, A, Kyle, R, Merlini, G, Miguel, JS, Ludwig, H, Hajek, R, et al.. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24. https://doi.org/10.1038/leu.2008.307.Search in Google Scholar PubMed
10. Jacobs, JFM, Turner, KA, Graziani, MS, Frinack, JL, Ettore, MW, Tate, JR, et al.. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med 2020;58:547–59. https://doi.org/10.1515/CCLM-2019-1105.Search in Google Scholar
11. Keren, DF, Alexanian, R, Goeken, JA, Gorevic, PD, Kyle, RA, Tomar, RH. Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123:106–7. https://doi.org/10.5858/1999-123-0106-gfcale.Search in Google Scholar
12. Keren, DF. Procedures for the evaluation of monoclonal immunoglobulins. Arch Pathol Lab Med 1999;123:126–32. https://doi.org/10.5858/1999-123-0126-pfteom.Search in Google Scholar
13. Graziani, M, Merlini, G, Petrini, C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41:338–46. https://doi.org/10.1515/CCLM.2003.054.Search in Google Scholar PubMed
14. Roden, AC, Lockington, KS, Tostrud, LJ, Katzmann, JA. Urine protein electrophoresis and immunoelectrophoresis using unconcentrated or minimally concentrated urine samples. Am J Clin Pathol 2008;130:141–5. https://doi.org/10.1309/6K33KTFA7A5VUQ1T.Search in Google Scholar PubMed
15. Dimopoulos, M, Kyle, R, Fermand, JP, Rajkumar, SV, San Miguel, J, Chanan-Khan, A, et al.. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701–5. https://doi.org/10.1182/BLOOD-2010-10-299529.Search in Google Scholar
16. Viedma, JA, Garrigós, N, Morales, S. Comparison of the sensitivity of 2 automated immunoassays with immunofixation electrophoresis for detecting urine Bence Jones proteins. Clin Chem 2005;51:1505–7. https://doi.org/10.1373/clinchem.2004.045880.Search in Google Scholar PubMed
17. Keren, DF, Schroeder, L. Challenges of measuring monoclonal proteins in serum. Clin Chem Lab Med 2016;54:947–61. https://doi.org/10.1515/cclm-2015-0862.Search in Google Scholar PubMed
18. Gupta, S, Comenzo, RL, Hoffman, BR, Fleisher, M. National academy of clinical biochemistry guidelines for the use of tumor markers in monoclonal gammopathies. NACB: Practice Guidelines and Recommendations for use of Tumor Markers in the Clinic Monoclonal Gammopathies (Section 3K) 2005.Search in Google Scholar
19. Cárdenas Fernández, MC, Pérez Surribas, D, Pérez Garay, R, Jiménez Jiménez, J, Gella Concustell, A, Zapico Muñiz, E, et al.. Vertical cutoff methods in serum protein electrophoresis for the measurement of monoclonal protein concentrations: which is best? Clin Chim Acta 2020;510:573–80. https://doi.org/10.1016/j.cca.2020.07.051.Search in Google Scholar PubMed
20. Turner, KA, Frinack, JL, Ettore, MW, Tate, JR, Graziani, MS, Jacobs, JFM, et al.. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clin Chem Lab Med 2020;58:533–46. https://doi.org/10.1515/cclm-2019-1104.Search in Google Scholar PubMed
21. Dejoie, T, Lakomy, D, Caillon, H, Pegourié, B, Decaux, O. Recommandations de l’IFM (Intergroupe francophone du myéLome) pour l’harmonisation de l’analyse des électrophorèses des protéines sériques et urinaires dans le diagnostic et le suivi du myéLome multiple. Ann Biol Clin (Paris) 2016;74:429–41. https://doi.org/10.1684/abc.2016.1166.Search in Google Scholar PubMed
22. Moss, MA. Moving towards harmonized reporting of serum and urine protein electrophoresis. Clin Chem Lab Med 2016;54:973–9. https://doi.org/10.1515/cclm-2015-0937.Search in Google Scholar PubMed
23. Booth, RA, McCudden, CR, Balion, CM, Blasutig, IM, Bouhtiauy, I, Rodriguez-Capote, K, et al.. Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group. Clin Biochem 2018;51:10–20. https://doi.org/10.1016/j.clinbiochem.2017.10.013.Search in Google Scholar PubMed
24. McCudden, CR, Booth, RA, Lin, DCC, McCurdy, A, Rupani, N, Kew, A. Synoptic reporting for protein electrophoresis and immunofixation. Clin Biochem 2018;51:21–8. https://doi.org/10.1016/j.clinbiochem.2017.09.020.Search in Google Scholar PubMed
25. Pérez Surribas, D, Cárdenas Fernández, MC, Zapico Muñiz, D. Recomendaciones sobre la separación electroforética de las proteínas plasmáticas en suero. Recomendación (2014). Documentos de la SEQC 2014;2015:91–104.Search in Google Scholar
26. Tate, J, Caldwell, G, Daly, J, Gillis, D, Jenkins, M, Jovanovich, S, et al.. Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Ann Clin Biochem 2012;49:242–56. https://doi.org/10.1258/acb.2011.011158.Search in Google Scholar PubMed
27. Ludwig, H, Miguel, JS, Dimopoulos, MA, Palumbo, A, Garcia Sanz, R, Powles, R, et al.. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014;28:981–92. https://doi.org/10.1038/LEU.2013.293.Search in Google Scholar
28. Long, TE, Indridason, OS, Palsson, R, Rognvaldsson, S, Love, TJ, Thorsteinsdottir, S, et al.. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J 2022;12:133. https://doi.org/10.1038/s41408-022-00732-3.Search in Google Scholar PubMed PubMed Central
29. Keren, DF, Bocsi, G, Billman, BL, Etzell, J, Faix, JD, Kumar, S, et al.. Laboratory detection and initial diagnosis of monoclonal gammopathies: guideline from the College of American Pathologists in collaboration with the American Association for Clinical Chemistry and the American Society for Clinical Pathology. Arch Pathol Lab Med 2022;146:575–90. https://doi.org/10.5858/arpa.2020-0794-cp.Search in Google Scholar
30. Katzmann, JA, Clark, R, Kyle, RA, Larson, DR, Therneau, TM, Melton, LJ, et al.. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013;27:208–12. https://doi.org/10.1038/leu.2012.189.Search in Google Scholar PubMed PubMed Central
31. Ludwig, H, Milosavljevic, D, Zojer, N, Faint, JM, Bradwell, AR, Hübl, W, et al.. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013;27:213–9. https://doi.org/10.1038/leu.2012.197.Search in Google Scholar PubMed PubMed Central
32. Harutyunyan, NM, Vardanyan, S, Ghermezi, M, Gottlieb, J, Berenson, A, Andreu-Vieyra, C, et al.. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. Br J Haematol 2016;174:81–7. https://doi.org/10.1111/bjh.14026.Search in Google Scholar PubMed
33. Lahuerta, JJ, Jiménez-Ubieto, A, Paiva, B, Martínez-López, J, González-Medina, J, López-Anglada, L, et al.. Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. Blood 2019;133:2664–8. https://doi.org/10.1182/blood.2019000671.Search in Google Scholar PubMed
34. Dejoie, T, Corre, J, Caillon, H, Moreau, P, Attal, M, Loiseau, HA. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia 2018;33:313–8. https://doi.org/10.1038/s41375-018-0339-y.Search in Google Scholar PubMed PubMed Central
35. Cárdenas, MC, Iñigo, B, Ortega, I, Palomar, MA, Menéndez, M, Plaza, P, et al.. Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients? Front Oncol 2022;12:1056293. https://doi.org/10.3389/FONC.2022.1056293/PDF.Search in Google Scholar
36. Rajkumar, SV, Harousseau, JL, Durie, B, Anderson, KC, Dimopoulos, M, Kyle, R, et al.. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691–5. https://doi.org/10.1182/blood-2010-10-299487.Search in Google Scholar PubMed PubMed Central
37. De Larrea, CF, Cibeira, MT, Elena, M, Arostegui, JI, Rosiñol, L, Rovira, M, et al.. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 2009;114:4954–6. https://doi.org/10.1182/blood-2009-06-224832.Search in Google Scholar PubMed
Supplementary Material
This article contains supplementary material (https://doi.org/10.1515/cclm-2023-0325).
© 2023 Walter de Gruyter GmbH, Berlin/Boston
